April 18, 2017
Via: CNBCShares of Eli Lilly closed down more than 4 percent Monday after the Food and Drug Administration rejected its drug to treat rheumatoid arthritis. Shares of Incyte, Lilly’s partner on the drug, baricitinib, closed down nearly 11 percent. Wall Street […]
April 23, 2024
March 28, 2024